Key result
Cardiomyocyte-specific overexpression of ERRγ or treatment with the agonist DY131 reduced infarct size and improved cardiac function by suppressing GBP5-mediated myocardial inflammation.
Why the study?
The transcriptional mechanisms regulating cardiomyocyte inflammation to mitigate post-ischemic injury following myocardial infarction remain poorly understood.
Does ERRγ activation reduce myocardial ischemic injury and inflammation in preclinical models of myocardial infarction?
Does ERRγ activation reduce myocardial ischemic injury and inflammation in preclinical models of myocardial infarction?
ERRγ activation represents a potential novel therapeutic target for attenuating post-MI injury by suppressing GBP5-mediated myocardial inflammation and pyroptosis.
Answers are grounded in this paper and cite their sources.
May attenuate post-MI injury in animal models; leaves open clinical translation of ERRγ agonists.
Myocardial inflammation plays a critical role in the progression of injury following myocardial infarction (MI), yet the transcriptional mechanisms regulating cardiomyocyte inflammation to mitigate post-ischemic injury remain poorly understood. This study elucidated the role of Estrogen-Related Receptor Gamma (ERRγ) in modulating the inflammatory response post-MI, demonstrating that ERRγ expression was downregulated in ischemic tissue and hypoxic neonatal mouse ventricular myocytes (NMVMs). Cardiomyocyte-specific overexpression of ERRγ reduced infarct size, improved cardiac function, and suppressed excessive myocardial inflammation and pyroptosis by binding to the GBP5 promoter, thereby inhibiting GBP5 transcription and reducing NLRP3 inflammasome assembly. The protective effects of ERRγ overexpression were reversed by overexpressing GBP5, and the ERRγ agonist DY131 also improved cardiac function after MI. These findings suggest that ERRγ activation reduces myocardial ischemic injury by regulating cardiomyocyte inflammation and pyroptosis, highlighting ERRγ as a potential novel therapeutic target for attenuating post-MI injury.
No takes yet. Share an insight, caveat, or question.
Qiu et al. (2025) studied Myocardial infarction (n=288). ERRγ overexpression (AAV9-cTNT-ERRγ) or ERRγ agonist DY131 vs. Control vector (AAV9-cTNT-NC/GFP) or PBS was evaluated on Cardiac function (LVEF, LVFS) and infarct size. Cardiomyocyte-specific overexpression of ERRγ or treatment with the agonist DY131 reduced infarct size and improved cardiac function by suppressing GBP5-mediated myocardial inflammation.
Synapse has enriched 10 related papers. Consider them for comparative context: